Trade Kiora Pharmaceuticals, Inc. - KPRX CFD

Trading Conditions

• Spread: 0.06
• Long position overnight feeLong position overnight feeMargin. Your investmentUS$1,000.00Overnight feeCharges from full value of position-0.026179 %(-US$1.05)Trade size with leverage ~ US$5,000.00Short position overnight fee ~ US$4,000.00Go to platform: -0.026179%
• Short position overnight feeShort position overnight feeMargin. Your investmentUS$1,000.00Overnight feeCharges from full value of position0.003957 %(US$0.16)Trade size with leverage ~ US$5,000.00Short position overnight fee ~ US$4,000.00Go to platform: 0.003957%
• Overnight fee time: 21:00 (UTC)
• Currency: USD
• Min traded quantity: 1
• Margin: 20
• Stock exchange: United States of America
• Commission on trade: 0%

• Margin. Your investment: US$1,000.00
• Overnight feeCharges from full value of position: -0.026179 %
  (-US$1.05)

• Margin. Your investment: US$1,000.00
• Overnight feeCharges from full value of position: 0.003957 %
  (US$0.16)

Key Stats

• Prev. Close: 0.46
• Open: 0.45
• 1-Year Change: -88.66%
• Day's Range: 0.45 - 0.48

Kiora Pharmaceuticals, Inc. Company profile

About Kiora Pharmaceuticals Inc

Kiora Pharmaceuticals, Inc., formerly Eyegate Pharmaceuticals, Inc., is a clinical-stage pharmaceutical company. The Company is engaged in developing and commercializing products for treating inflammatory and immune diseases with a focus on the eye and nervous system. The Company's pipeline consists of three assets including KIO-101, KIO-301, and KIO-201 in early to late-stage development for both common and rare eye diseases. KIO-101, is a non-steroidal, immuno-modulatory and small-molecule inhibitor of Dihydroorotate Dehydrogenase (DHODH). Its KIO-301, is a light-sensitive small molecule that acts as a reversible photoswitch, designed to restore the eyes' ability to perceive and interpret light in visually impaired patients. The Company's KIO-201, which is a form of the natural polymer hyaluronic acid, designed to protect the ocular surface to permit re-epithelialization of the cornea and improve ocular surface integrity.

Financial summary

BRIEF: For the nine months ended 30 September 2021, Kiora Pharmaceuticals Inc revenues was not reported. Net loss increased 41% to $8M. Higher net loss reflects Research and Development Expense - Balan increase of 73% to $4.2M (expense), General and Administrative Expense - Bal increase of 26% to $3.5M (expense), Stock-based Compensation in SGA increase of 19% to $453K (expense).